Meeting
2020 Gastrointestinal Cancers Symposium
Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer.
Authors
Asmita Chopra
Department of Surgery, University of Pittsburgh, Pittsburgh, PA
Asmita Chopra , Jacob C. Hodges , Adam Olson , Steven A. Burton , Kenneth K. Lee , Nathan Bahary , Aatur D. Singhi , Brian A. Boone , Michael T. Lotze , Melissa E. Hogg , Herbert Zeh III, Amer H. Zureikat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 727)
Abstract #
727
Poster Bd #
L16
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Evaluating associations of diabetes, insulin use, and BMI with efficacy in patients with resected pancreatic cancer: An ancillary analysis of NRG Oncology/RTOG 9704.
First Author: Theodore S. Hong
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Impact of patient characteristics and treatment patterns on outcomes in potentially resectable pancreatic cancer (PC).
First Author: Andrew Steinmetz
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka